J. Dennie

发表

A Phase I, Single‐Ascending‐Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DS‐2969b, a Novel GyrB Inhibitor

G. Senaldi, N. Masuda, M. Yamada, 2018, Journal of clinical pharmacology.

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of DS‐3801b, a Motilin Receptor Agonist, in Healthy Subjects

G. Senaldi, G. Atiee, V. Warren, 2017, Journal of clinical pharmacology.

Hypersensitivity incidence after sugammadex administration in healthy subjects: a randomised controlled trial

J. McCrea, D. Gutstein, C. Assaid, 2018, British journal of anaesthesia.

Effect of Sugammadex on QT/QTc Interval Prolongation when Combined with QTc-Prolonging Sevoflurane or Propofol Anaesthesia

P. De Kam, S. Ramael, M. W. van den Heuvel, 2013, Clinical Drug Investigation.

Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects.

M. Moerland, M. V. van Lierop, P. De Kam, 2014, International journal of clinical pharmacology and therapeutics.

Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: a positron emission tomography study with fluorine-18-labeled setoperone.

P. Liddle, R. Lam, T. Ruth, 1999, Archives of general psychiatry.

Asenapine pharmacokinetics and tolerability in a pediatric population

R. Findling, M. Troyer, V. Reddy, 2018, Drug design, development and therapy.

An LC-MRM method for measuring intestinal triglyceride assembly using an oral stable isotope-labeled fat challenge.

Michael E. Lassman, E. Parks, O. Laterza, 2016, Bioanalysis.

Quantification, Variability, and Reproducibility of Basal Skeletal Muscle Glucose Uptake in Healthy Humans Using 18F-FDG PET/CT

Koen Van Laere, Olivier Gheysens, K. Van Laere, 2015, The Journal of Nuclear Medicine.

Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects

G. Senaldi, N. Masuda, J. Pav, 2018, Antimicrobial Agents and Chemotherapy.